Company intelligence / Profile preview

IGXBio

Fairway, Kansas, United States

Ownership: Private
Development stage: Other

Overview

GenePro® has demonstrated production of CD8+ memory cells in non-human primates similar to those produced by Elite Controllers of HIV (individuals who control HIV progression without therapeutic drugs). The therapy is designed to promote anti-HIV immune response and facilitate virus control in HIV-infected subjects.

Therapeutic areas: Infectious Diseases
Modalities: DNA vaccine
Industry: Biotech

Drug pipeline

1 asset

GenePro

Unknown

Partnerships

Cannabis Science, Inc. (collaborative drug development deal announced May 2015 to combine GenePro® with CS-TATI-1, a cannabinoid-based therapeutic, to explore synergistic anti-inflammatory and anti-HIV effects)

Beyond the preview

Go deeper on IGXBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGXBio.

Explore the full profile